RecruitingPHASE1, PHASE2NCT03707808

Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab

Studying Dendritic cell tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Universitair Ziekenhuis Brussel
Intervention
intratumoral injection of autologous CD1c (BDCA-1)+ myDC(drug)
Enrollment
18 target
Eligibility
18 years · All sexes
Timeline
20182025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03707808 on ClinicalTrials.gov

Other trials for Dendritic cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Dendritic cell tumor

← Back to all trials